Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability

• US 20050079138A1
• Filed: 09/30/2004
• Published: 04/14/2005
• Est. Priority Date: 12/19/2002
• Status: Abandoned Application

• Current Assignee: Acusphere Incorporated
• Original Assignee: Acusphere Incorporated
• Inventors: Brito, Luis A., Altreuter, David, Narasimhan, Sridhar, Chickering, Donald E. III, Bernstein, Howard, Jain, Rajeev A., Straub, Julie A., Reese, Shaina, Huang, Eric K.
• Application Number:
  US10/955,261
• Publication Number:
  US 20050079138A1
• Time in Patent Office: Days
• US Class Current: 424/46
• CPC Class Codes: A61K 9/0075 for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• CPC Class Codes: A61K 9/145 with organic compounds
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: B01D 1/18 to obtain dry solids B01D1/24 takes precedence
• CPC Class Codes: B01J 2/04 in a gaseous medium if combined with suspending the material in a gas, e.g. fluidised beds B01J2/16

Abstract

Methods are provided for making a dry powder blend pharmaceutical formulation, comprising the steps of: (a) providing microparticles which comprise a pharmaceutical agent; (b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and (c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b). The method can further include dispersing the dry powder blend pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle to make an formulation suitable for injection. Alternatively, the method can further include processing the dry powder blend pharmaceutical formulation into a solid oral dosage form. In one embodiment, the microparticles of step (a) are formed by a solvent precipitation or crystallization process.

Claims

1. A method for making a dry powder blend pharmaceutical formulation, comprising the steps of:

(a) providing microparticles which comprise a pharmaceutical agent;

(b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and

(c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b).

2. The method of claim 1, wherein the microparticles of step (a) are crystals of the pharmaceutical agent.

3. The method of claim 1, wherein the microparticles of step (a) are formed by a solvent precipitation or crystallization process.

4. The method of claim 1, wherein the microparticles are formed by a spray drying process.

5. The method of claim 1, wherein the excipient particles have a volume average diameter that is greater than the volume average diameter of the microparticles.

6. The method of claim 1, wherein the excipient particles have a volume average size between 10 and 500 microns.

7. The method of claim 6, wherein the excipient particles have a volume average size between 20 and 200 microns.

8. The method of claim 7, wherein the excipient particles have a volume average size between 40 and 100 microns.

9. The method of claim 1, wherein the excipient is selected from the group consisting of bulking agents, preservatives, wetting agents, surface active agents, osmotic agents, pharmaceutically acceptable carriers, diluents, binders, disintegrants, glidants, lubricants, and combinations thereof.

10. The method of claim 1, wherein the excipient is selected from the group consisting of lipids, sugars, amino acids, and polyoxyethylene sorbitan fatty acid esters, and combinations thereof.

11. The method of claim 1, wherein the excipient is selected from the group consisting of lactose, mannitol, sorbitol, trehalose, xylitol, erythritol, and combinations thereof.

12. The method of claim 1, wherein the excipient is selected from the group consisting of binders, disintegrants, glidants, diluents, coloring agents, flavoring agents, sweeteners, lubricants, and combinations thereof, which are suitable for use in a solid oral dosage form.

13. The method of claim 1, wherein the blending is conducted using a tumbler mixer.

14. The method of claim 1, wherein two or more excipients are blended with the microparticles.

15. The method of claim 14, wherein the two or more excipients are blended together in a wet or dry blending step to form an excipient blend, which is then blended with the microparticles.

16. The method of claim 14, wherein the two or more excipients and the microparticles are blended together in a single step.

17. The method of claim 1, wherein the jet milling is performed with a feed gas and/or grinding gas supplied to the jet mill at a temperature of less than about 100°

C.

18. The method of claim 1, wherein the microparticles consist essentially of a therapeutic or prophylactic pharmaceutical agent.

19. The method of claim 1, wherein the microparticles have a number average size between 1 and 20 μ

m.

20. The method of claim 1, wherein the microparticles have a volume average size between 2 and 50 μ

m.

21. The method of claim 1, wherein the microparticles have an aerodynamic diameter between 1 and 50 μ

m.

22. The method of claim 1, wherein the microparticles comprise microspheres having voids or pores therein.

23. The method of claim 1, wherein the pharmaceutical agent is a therapeutic or prophylactic agent.

24. The method of claim 23, wherein the therapeutic or prophylactic agent is selected from the group consisting of non-steroidal anti-inflammatory agents, corticosteroids, anti-neoplastics, anti-microbial agents, anti-virals, anti-bacterial agents, anti-fungals, anti-asthmatics, bronchiodilators, antihistamines, immunosuppressive agents, anti-anxiety agents, sedatives/hypnotics, anti-psychotic agents, anticonvulsants, and calcium channel blockers.

25. The method of claim 23, wherein the therapeutic or prophylactic agent is hydrophobic and the microparticles comprise microspheres having voids or pores therein.

26. The method of claim 23, wherein the therapeutic or prophylactic agent is selected from the group consisting of celecoxib, rofecoxib, docetaxel, paclitaxel, acyclovir, albuterol, alprazolam, amiodaron, amoxicillin, anagrelide, bactrim, beclomethasone dipropionate, biaxin, budesonide, bulsulfan, calcitonin, carbamazepine, ceftazidime, cefprozil, ciprofloxacin, clarithromycin, clozapine, cyclosporine, diazepam, estradiol, etodolac, famciclovir, fenofibrate, fexofenadine, fomoterol, flunisolide, fluticasone propionate, gemcitabine, ganciclovir, granulocyte colony-stimulating factor, insulin, itraconazole, lamotrigine, leuprolide, loratidine, lorazepam, meloxicam, mesalamine, minocycline, modafinil, mometasone, nabumetone, nelfinavir mesylate, olanzapine, oxcarbazepine, parathyroid hormone-related peptide, phenyloin, progesterone, propfol, ritinavir, salmeterol, sirolimus, SN-38, somatostatin, sulfamethoxazole, sulfasalazine, testosterone, tacrolimus, tiagabine, tizanidine, triamcinolone acetonide, trimethoprim, valsartan, voriconazole, zafirlukast, zileuton, and ziprasidone.

27. The method of claim 1, wherein the pharmaceutical agent comprises a diagnostic agent.

28. The method of claim 27, wherein the diagnostic agent is an ultrasound contrast agent.

29. The method of claim 1, wherein the microparticles comprise a shell material surrounding a core of the pharmaceutical agent.

30. The method of claim 29, wherein the shell material is selected from the group consisting of polymers, lipids, sugars, and amino acids.

31. The method of claim 1, wherein the microparticles further comprise a biocompatible polymer.

32. The method of claim 31, wherein the biodegradable polymer is selected from the group consisting poly(hydroxy acids), polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), blends thereof, and copolymers thereof.

33. The method of claim 1, wherein the microparticles of step (a) are jet milled before step (b).

34. The method of claim 1, wherein the excipient particles are jet milled before being blended in step (b).

35. The method of claim 1, further comprising dispersing the dry powder blend pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle.

36. The method of claim 1, further comprising processing the dry powder blend pharmaceutical formulation into a solid oral dosage form.

37. A pharmaceutical composition comprising the dry powder blend pharmaceutical formulation made by the method of claim 1.

38. The composition of claim 37, which is an injectable dosage form.

39. A method for making a solid oral dosage form of a pharmaceutical agent, comprising the steps of:

(a) providing microparticles which comprise a pharmaceutical agent;

(b) blending the microparticles with at least one excipient in the form of particles to form a powder blend;

(c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b); and

(d) processing the dry powder blend pharmaceutical formulation into a solid oral dosage form.

40. A solid oral dosage form, comprising a pharmaceutical agent, made by the method of claim 39.

41. The dosage form of claim 40, which is a capsule.

42. The dosage form of claim 40, which is a tablet.

43. The dosage form of claim 40, which is an orally disintegrating tablet.

44. The dosage form of claim 40, which is a wafer.